{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:46:51Z","timestamp":1790344011375,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173780"],"award-info":[{"award-number":["82173780"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["DQCP20\/21MS04"],"award-info":[{"award-number":["DQCP20\/21MS04"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.dmd.2025.100165","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:55:51Z","timestamp":1758131751000},"page":"100165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical pharmacokinetics and immunogenicity evaluation of a trophoblast cell surface antigen 2\u2013targeted antibody-drug conjugate, FDA018, in patients with epithelial malignant solid tumors"],"prefix":"10.1016","volume":"53","author":[{"given":"Minlu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinxin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100165_bib1","article-title":"Racial and regional disparities of triple negative breast cancer incidence rates in the United States: an analysis of 2011\u20132019 NPCR and SEER incidence data","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.dmd.2025.100165_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.dmd.2025.100165_bib3","first-page":"647","article-title":"Research progress on molecular subtyping and modern treatment of triple-negative breast cancer","volume":"15","author":"Tong","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"15_suppl","key":"10.1016\/j.dmd.2025.100165_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e14651","article-title":"Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC)","volume":"37","author":"Khoury","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100165_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41523-022-00439-5","article-title":"Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer\u2014phase 3 ASCENT study subanalysis","volume":"8","author":"Carey","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.dmd.2025.100165_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejmech.2019.02.017","article-title":"Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: sacituzumab govitecan and labetuzumab govitecan","volume":"167","author":"Dong","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.dmd.2025.100165_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103853","article-title":"Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis","volume":"79","author":"Dacoregio","year":"2025","journal-title":"Breast"},{"issue":"8_suppl","key":"10.1016\/j.dmd.2025.100165_bib8","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1158\/1538-7445.AM10-2439","article-title":"Abstract 2439: Cross-linker evaluation in the design of antibody-SN-38 conjugates for cancer therapy","volume":"70","author":"Moon","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.dmd.2025.100165_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/antib7040041","article-title":"ADME considerations and bioanalytical strategies for pharmacokinetic assessments of antibody-drug conjugates","volume":"7","author":"Mou","year":"2018","journal-title":"Antibodies (Basel)"},{"issue":"10","key":"10.1016\/j.dmd.2025.100165_bib10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1124\/dmd.123.001313","article-title":"Bioanalytical assays for pharmacokinetic and biodistribution study of antibody-drug conjugates","volume":"51","author":"Yin","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"17","key":"10.1016\/j.dmd.2025.100165_bib11","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dmd.2025.100165_bib14","article-title":"International Conference on Harmonisation of Technical Requirements for Registration Of Pharmaceuticals For Human Use (ICH)","volume":"S9","year":"2009","journal-title":"Nonclinical evaluation for anticancer pharmaceuticals"},{"issue":"8","key":"10.1016\/j.dmd.2025.100165_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ddr.21461","article-title":"Dose translation between laboratory animals and human in preclinical and clinical phases of drug development","volume":"79","author":"Nair","year":"2018","journal-title":"Drug Dev Res"},{"issue":"4","key":"10.1016\/j.dmd.2025.100165_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100165_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115032","article-title":"Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: critical role of gut Ugt","volume":"398","author":"Sun","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmd.2025.100165_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176614","article-title":"Mechanisms and emerging strategies for irinotecan-induced diarrhea","volume":"974","author":"Xu","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dmd.2025.100165_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116964","article-title":"LBA and LC-MS\/MS based comprehensive bioanalytical methods for FDA018, a Trop-2 targeted antibody-drug conjugate","volume":"264","author":"Cheng","year":"2025","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.dmd.2025.100165_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/antib10020020","article-title":"Clinical Pharmacology of antibody-drug conjugates","volume":"10","author":"Mahmood","year":"2021","journal-title":"Antibodies (Basel)"},{"issue":"2","key":"10.1016\/j.dmd.2025.100165_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds","volume":"60","author":"An","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100165_bib24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/dmd.119.089276","article-title":"Evaluation of quantitative relationship between target expression and antibody-drug conjugate exposure inside cancer cells","volume":"48","author":"Sharma","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2025.100165_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pst.326","article-title":"Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion","volume":"8","author":"Hummel","year":"2009","journal-title":"Pharm Stat"},{"issue":"19","key":"10.1016\/j.dmd.2025.100165_bib26","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:29:23Z","timestamp":1778664563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625094747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0090955625094747"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100165","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacokinetics and immunogenicity evaluation of a trophoblast cell surface antigen 2\u2013targeted antibody-drug conjugate, FDA018, in patients with epithelial malignant solid tumors","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100165"}}